|
|
|
|
| LEADER |
01000caa a2200265 4500 |
| 001 |
OLC1974872459 |
| 003 |
DE-627 |
| 005 |
20220222171436.0 |
| 007 |
tu |
| 008 |
160609s2016 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a PQ20160610
|
| 035 |
|
|
|a (DE-627)OLC1974872459
|
| 035 |
|
|
|a (DE-599)GBVOLC1974872459
|
| 035 |
|
|
|a (PRQ)g546-1a0db3a40fcad099607111fd816a5fefa14ba4cec6bd3c7a72a696b0b6be5cd70
|
| 035 |
|
|
|a (KEY)0040068820160000213000701124developmentofacosteffectiveovinepolyclonalantibody
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 610
|q DNB
|
| 084 |
|
|
|a XA 10000
|q AVZ
|2 rvk
|
| 084 |
|
|
|a 44.75
|2 bkl
|
| 084 |
|
|
|a 44.00
|2 bkl
|
| 100 |
1 |
|
|a Dowall, Stuart David
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 520 |
|
|
|a The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease.
|
| 540 |
|
|
|a Nutzungsrecht: © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.
|
| 650 |
|
4 |
|a Care and treatment
|
| 650 |
|
4 |
|a Ebola virus infections
|
| 650 |
|
4 |
|a Ebola virus
|
| 650 |
|
4 |
|a Research
|
| 700 |
1 |
|
|a Callan, Jo
|4 oth
|
| 700 |
1 |
|
|a Zeltina, Antra
|4 oth
|
| 700 |
1 |
|
|a Al-Abdulla, Ibrahim
|4 oth
|
| 700 |
1 |
|
|a Strecker, Thomas
|4 oth
|
| 700 |
1 |
|
|a Fehling, Sarah K
|4 oth
|
| 700 |
1 |
|
|a Krähling, Verena
|4 oth
|
| 700 |
1 |
|
|a Bosworth, Andrew
|4 oth
|
| 700 |
1 |
|
|a Rayner, Emma
|4 oth
|
| 700 |
1 |
|
|a Taylor, Irene
|4 oth
|
| 700 |
1 |
|
|a Charlton, Sue
|4 oth
|
| 700 |
1 |
|
|a Landon, John
|4 oth
|
| 700 |
1 |
|
|a Cameron, Ian
|4 oth
|
| 700 |
1 |
|
|a Hewson, Roger
|4 oth
|
| 700 |
1 |
|
|a Nasidi, Abdulsalami
|4 oth
|
| 700 |
1 |
|
|a Bowden, Thomas A
|4 oth
|
| 700 |
1 |
|
|a Carroll, Miles W
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t The journal of infectious diseases
|d Cary, NC : Oxford Univ. Press, 1904
|g 213(2016), 7, Seite 1124
|w (DE-627)129078301
|w (DE-600)3019-3
|w (DE-576)014410869
|x 0022-1899
|7 nnns
|
| 773 |
1 |
8 |
|g volume:213
|g year:2016
|g number:7
|g pages:1124
|
| 856 |
4 |
2 |
|u http://www.ncbi.nlm.nih.gov/pubmed/26715676
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a GBV_ILN_168
|
| 912 |
|
|
|a GBV_ILN_2004
|
| 912 |
|
|
|a GBV_ILN_4012
|
| 912 |
|
|
|a GBV_ILN_4219
|
| 936 |
r |
v |
|a XA 10000
|
| 936 |
b |
k |
|a 44.75
|q AVZ
|
| 936 |
b |
k |
|a 44.00
|q AVZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 213
|j 2016
|e 7
|h 1124
|
